Lung Neoplasms Archives | MSD Oncology Clinical Trials

English

Coformulation of Pembrolizumab/Vibostolimab Versus Pembrolizumab Monotherapy for Programmed Cell Death 1 Ligand 1 Positive Metastatic Non-Small Cell Lung Cancer

March 7, 2022

The primary hypotheses are that coformulated pembrolizumab/vibostolimab is superior to pembrolizumab alone with respect to (1) overall survival (OS) in participants with programmed cell death 1 ligand 1 (PD-L1) tumor proportion

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer

March 7, 2022

By clique_admin

The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with

Condition: Lung Neoplasms

Condition: Lung Neoplasms

Coformulation of Pembrolizumab/Vibostolimab Versus Pembrolizumab Monotherapy for Programmed Cell Death 1 Ligand 1 Positive Metastatic Non-Small Cell Lung Cancer

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer